A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy Participants

PHASE3CompletedINTERVENTIONAL
Enrollment

1,574

Participants

Timeline

Start Date

February 15, 2021

Primary Completion Date

July 22, 2021

Study Completion Date

July 22, 2021

Conditions
SARS-CoV-2 InfectionCOVID-19
Interventions
BIOLOGICAL

BNT162b2

Intramuscular injection

BIOLOGICAL

BNT162b2.B.1.351

Intramuscular injection

Trial Locations (17)

28401

Accellacare - Wilmington, Wilmington

30281

Clinical Research Atlanta, Stockbridge

32801

Clinical Neuroscience Solutions, Orlando

33012

Indago Research & Health Center, Inc, Hialeah

33024

Research Centers of America, Hollywood

40004

Kentucky Pediatric/Adult Research, Bardstown

45206

Cincinnati Children's Hospital Medical Center, Cincinnati

77081

Texas Center for Drug Development, Inc., Houston

77375

Martin Diagnostic Clinic, Tomball

78229

Clinical Trials of Texas, LLC, San Antonio

83646

Solaris Clinical Research, Meridian

84121

J. Lewis Research, Inc. / Foothill Family Clinic South, Salt Lake City

94611

Kaiser Permanente Oakland, Oakland

96814

East-West Medical Research Institute, Honolulu

06460

Clinical Research Consulting, Milford

08869

Amici Clinical Research LLC, Raritan

45229-3039

Cincinnati Children's Hospital Medical Center, Cincinnati

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

BioNTech SE

INDUSTRY

NCT04713553 - A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy Participants | Biotech Hunter | Biotech Hunter